Six-Week Randomized Controlled Trial to Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

Robin Wood, Keikawus Arasteh, Hans Jürgen Stellbrink, Eugenio Teofilo, François Raffi, Richard B Pollard, Joseph Eron, Jane Yeo, Judith Millard, Mary Beth Wire, Odin J. Naderer

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV) protease inhibitors amprenavir (Agenerase) 1,200 mg twice daily (BID) and the amprenavir prodrug GW433908, a formulation that substantially reduces the number of tablets per dose compared with amprenavir, at doses of 1,395 mg and 1,860 mg BID, in combination with abacavir 300 mg BID and lamivudine 150 mg BID in patients with HIV infection. Overall, 78 patients received study treatment. Compared with amprenavir 1,200 mg BID, both GW433908 1,395 mg BID and GW433908 1,860 mg BID delivered equivalent steady-state (ss) values for area under the plasma amprenavir concentration-time curve (AUC) at the end of a dosing interval (τ), lower maximum plasma amprenavir concentrations (30% lower), and higher plasma amprenavir concentrations at the end of a dosing interval (28% higher for GW433908 1,395 mg BID and 46% higher for GW433908 1,860 mg BID). Time-variant plasma amprenavir pharmacokinetics were observed with reductions in plasma amprenavir exposure over the first 4 weeks of dosing; the decrease in plasma amprenavir AUCτ,ss versus the AUC from 0 h to ∞ was 27% for GW43308 1,395 mg, 45% for GW433908 1,860 mg, and 23% for amprenavir 1,200 mg. All three regimens reduced plasma HIV-1 RNA (∼2 log10 copies/ml) and increased CD4 + cell counts (∼100 cells/mm3) over the initial 28 days. Adverse event profiles were consistent with those previously reported for amprenavir. Although not statistically tested, the GW433908 groups appeared to have fewer gastrointestinal symptoms. In conclusion, the protease inhibitor GW433908 delivered comparable plasma amprenavir concentrations to those delivered by amprenavir 1,200 mg BID. GW433908, in combination with abacavir and lamivudine, demonstrated potent antiviral activity and was generally well tolerated over a 4-week period.

Original languageEnglish (US)
Pages (from-to)116-123
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume48
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Antiviral Agents
HIV-1
Randomized Controlled Trials
Pharmacokinetics
Area Under Curve
fosamprenavir
amprenavir
Protease Inhibitors
HIV
Lamivudine
Prodrugs
Virus Diseases
CD4 Lymphocyte Count
Tablets

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Six-Week Randomized Controlled Trial to Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients. / Wood, Robin; Arasteh, Keikawus; Stellbrink, Hans Jürgen; Teofilo, Eugenio; Raffi, François; Pollard, Richard B; Eron, Joseph; Yeo, Jane; Millard, Judith; Wire, Mary Beth; Naderer, Odin J.

In: Antimicrobial Agents and Chemotherapy, Vol. 48, No. 1, 01.2004, p. 116-123.

Research output: Contribution to journalArticle

Wood, Robin ; Arasteh, Keikawus ; Stellbrink, Hans Jürgen ; Teofilo, Eugenio ; Raffi, François ; Pollard, Richard B ; Eron, Joseph ; Yeo, Jane ; Millard, Judith ; Wire, Mary Beth ; Naderer, Odin J. / Six-Week Randomized Controlled Trial to Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients. In: Antimicrobial Agents and Chemotherapy. 2004 ; Vol. 48, No. 1. pp. 116-123.
@article{b3c968baf7c849d1ab286a0c1295f48f,
title = "Six-Week Randomized Controlled Trial to Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients",
abstract = "This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV) protease inhibitors amprenavir (Agenerase) 1,200 mg twice daily (BID) and the amprenavir prodrug GW433908, a formulation that substantially reduces the number of tablets per dose compared with amprenavir, at doses of 1,395 mg and 1,860 mg BID, in combination with abacavir 300 mg BID and lamivudine 150 mg BID in patients with HIV infection. Overall, 78 patients received study treatment. Compared with amprenavir 1,200 mg BID, both GW433908 1,395 mg BID and GW433908 1,860 mg BID delivered equivalent steady-state (ss) values for area under the plasma amprenavir concentration-time curve (AUC) at the end of a dosing interval (τ), lower maximum plasma amprenavir concentrations (30{\%} lower), and higher plasma amprenavir concentrations at the end of a dosing interval (28{\%} higher for GW433908 1,395 mg BID and 46{\%} higher for GW433908 1,860 mg BID). Time-variant plasma amprenavir pharmacokinetics were observed with reductions in plasma amprenavir exposure over the first 4 weeks of dosing; the decrease in plasma amprenavir AUCτ,ss versus the AUC from 0 h to ∞ was 27{\%} for GW43308 1,395 mg, 45{\%} for GW433908 1,860 mg, and 23{\%} for amprenavir 1,200 mg. All three regimens reduced plasma HIV-1 RNA (∼2 log10 copies/ml) and increased CD4 + cell counts (∼100 cells/mm3) over the initial 28 days. Adverse event profiles were consistent with those previously reported for amprenavir. Although not statistically tested, the GW433908 groups appeared to have fewer gastrointestinal symptoms. In conclusion, the protease inhibitor GW433908 delivered comparable plasma amprenavir concentrations to those delivered by amprenavir 1,200 mg BID. GW433908, in combination with abacavir and lamivudine, demonstrated potent antiviral activity and was generally well tolerated over a 4-week period.",
author = "Robin Wood and Keikawus Arasteh and Stellbrink, {Hans J{\"u}rgen} and Eugenio Teofilo and Fran{\cc}ois Raffi and Pollard, {Richard B} and Joseph Eron and Jane Yeo and Judith Millard and Wire, {Mary Beth} and Naderer, {Odin J.}",
year = "2004",
month = "1",
doi = "10.1128/AAC.48.1.116-123.2004",
language = "English (US)",
volume = "48",
pages = "116--123",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Six-Week Randomized Controlled Trial to Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

AU - Wood, Robin

AU - Arasteh, Keikawus

AU - Stellbrink, Hans Jürgen

AU - Teofilo, Eugenio

AU - Raffi, François

AU - Pollard, Richard B

AU - Eron, Joseph

AU - Yeo, Jane

AU - Millard, Judith

AU - Wire, Mary Beth

AU - Naderer, Odin J.

PY - 2004/1

Y1 - 2004/1

N2 - This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV) protease inhibitors amprenavir (Agenerase) 1,200 mg twice daily (BID) and the amprenavir prodrug GW433908, a formulation that substantially reduces the number of tablets per dose compared with amprenavir, at doses of 1,395 mg and 1,860 mg BID, in combination with abacavir 300 mg BID and lamivudine 150 mg BID in patients with HIV infection. Overall, 78 patients received study treatment. Compared with amprenavir 1,200 mg BID, both GW433908 1,395 mg BID and GW433908 1,860 mg BID delivered equivalent steady-state (ss) values for area under the plasma amprenavir concentration-time curve (AUC) at the end of a dosing interval (τ), lower maximum plasma amprenavir concentrations (30% lower), and higher plasma amprenavir concentrations at the end of a dosing interval (28% higher for GW433908 1,395 mg BID and 46% higher for GW433908 1,860 mg BID). Time-variant plasma amprenavir pharmacokinetics were observed with reductions in plasma amprenavir exposure over the first 4 weeks of dosing; the decrease in plasma amprenavir AUCτ,ss versus the AUC from 0 h to ∞ was 27% for GW43308 1,395 mg, 45% for GW433908 1,860 mg, and 23% for amprenavir 1,200 mg. All three regimens reduced plasma HIV-1 RNA (∼2 log10 copies/ml) and increased CD4 + cell counts (∼100 cells/mm3) over the initial 28 days. Adverse event profiles were consistent with those previously reported for amprenavir. Although not statistically tested, the GW433908 groups appeared to have fewer gastrointestinal symptoms. In conclusion, the protease inhibitor GW433908 delivered comparable plasma amprenavir concentrations to those delivered by amprenavir 1,200 mg BID. GW433908, in combination with abacavir and lamivudine, demonstrated potent antiviral activity and was generally well tolerated over a 4-week period.

AB - This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV) protease inhibitors amprenavir (Agenerase) 1,200 mg twice daily (BID) and the amprenavir prodrug GW433908, a formulation that substantially reduces the number of tablets per dose compared with amprenavir, at doses of 1,395 mg and 1,860 mg BID, in combination with abacavir 300 mg BID and lamivudine 150 mg BID in patients with HIV infection. Overall, 78 patients received study treatment. Compared with amprenavir 1,200 mg BID, both GW433908 1,395 mg BID and GW433908 1,860 mg BID delivered equivalent steady-state (ss) values for area under the plasma amprenavir concentration-time curve (AUC) at the end of a dosing interval (τ), lower maximum plasma amprenavir concentrations (30% lower), and higher plasma amprenavir concentrations at the end of a dosing interval (28% higher for GW433908 1,395 mg BID and 46% higher for GW433908 1,860 mg BID). Time-variant plasma amprenavir pharmacokinetics were observed with reductions in plasma amprenavir exposure over the first 4 weeks of dosing; the decrease in plasma amprenavir AUCτ,ss versus the AUC from 0 h to ∞ was 27% for GW43308 1,395 mg, 45% for GW433908 1,860 mg, and 23% for amprenavir 1,200 mg. All three regimens reduced plasma HIV-1 RNA (∼2 log10 copies/ml) and increased CD4 + cell counts (∼100 cells/mm3) over the initial 28 days. Adverse event profiles were consistent with those previously reported for amprenavir. Although not statistically tested, the GW433908 groups appeared to have fewer gastrointestinal symptoms. In conclusion, the protease inhibitor GW433908 delivered comparable plasma amprenavir concentrations to those delivered by amprenavir 1,200 mg BID. GW433908, in combination with abacavir and lamivudine, demonstrated potent antiviral activity and was generally well tolerated over a 4-week period.

UR - http://www.scopus.com/inward/record.url?scp=9144240623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144240623&partnerID=8YFLogxK

U2 - 10.1128/AAC.48.1.116-123.2004

DO - 10.1128/AAC.48.1.116-123.2004

M3 - Article

C2 - 14693528

AN - SCOPUS:9144240623

VL - 48

SP - 116

EP - 123

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -